Celularity Inc
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 170 PARK AVE, FLORHAM PARK, NJ, 07932
Mailing Address 170 PARK AVE, FLORHAM PARK, NJ, 07932
Phone (908) 768-2170
Fiscal Year End 1231
EIN 831702591
Financial Overview
FY2024
-$57.89M
Net Income
$123.84M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 11, 2026 | View on SEC |
| 8-K Current report of material events | January 21, 2026 | View on SEC |
| 4/A Insider transaction amendment | January 15, 2026 | View on SEC |
| 4/A Insider transaction amendment | January 15, 2026 | View on SEC |
| 4/A Insider transaction amendment | January 15, 2026 | View on SEC |
| 4/A Insider transaction amendment | January 15, 2026 | View on SEC |
| 4 Insider stock transaction report | January 14, 2026 | View on SEC |
| 4 Insider stock transaction report | January 14, 2026 | View on SEC |
| 4 Insider stock transaction report | January 14, 2026 | View on SEC |
| 4 Insider stock transaction report | January 14, 2026 | View on SEC |
Material Events
8-K Legal Issue December 5, 2025
Medium Impact
- Celularity Inc. received a warning letter from the U.S. Food and Drug Administration (FDA) regarding the marketing of its product Interfyl.
- The FDA stated that Celularity's marketing materials for Interfyl included 'outcome-based claims' and mentioned 'metabolic activity within the body' that go beyond its current regulatory designation.
Related Companies
Companies in the same industry (SIC: 2834)
Werewolf Therapeutics, Inc.
HOWL Pharmaceutical Preparations
Zenas BioPharma, Inc.
ZBIO Pharmaceutical Preparations
Centessa Pharmaceuticals plc
CNTA Pharmaceutical Preparations
Karyopharm Therapeutics Inc.
KPTI Pharmaceutical Preparations
VERTEX PHARMACEUTICALS INC / MA
VRTX Pharmaceutical Preparations
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.